News

On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December

Viro announced that it has received a Complete Response letter from FDA related to its supplemental Biologics License Application (sBLA) for Cinryze as a treatment for acute attacks

These data will be presented on June 6, 2009 at the European Hematology Association’s (EHA) 14th Congress in Berlin, Germany. Researchers analyzed follow up data from patients enrolled

AVI BioPharma and Charley’s Fund, a not for profit organization, have amended their existing sponsored research agreement to provide for an additional $3 million in sponsored research funds.

Novavax, and the Division of Microbiology and Infectious Diseases (DMID) have entered into an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against

Lpath has been awarded a $3 million grant by the National Cancer Institute (NCI). The funds will support the continued clinical development of Lpath’s drug candidate, ASONEP, which

Abbott and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott’s Trilipix (fenofibric acid). Its a medication to be used alone or

Acces has declared that new Thiarabine preclinical efficacy data will shortly be published, demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either

Santaris Pharma has announced that the cancer drug EZN-2968, an inhibitor of HIF, is being evaluated in patients with solid tumors and lymphoma. EZN-2968 is well tolerated, and